trending Market Intelligence /marketintelligence/en/news-insights/trending/j-3gri0ic5m7btouk1nlwa2 content esgSubNav
In This List

Nabriva Therapeutics appoints chief medical officer

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Nabriva Therapeutics appoints chief medical officer

Nabriva Therapeutics plc named Jennifer Schranz as its chief medical officer to lead the clinical development and medical affairs of the Dublin-based company.

Nabriva is a clinical-stage biopharmaceutical company developing treatments for infections.

Schranz is joining the company from Shire Plc where she was in charge of the clinical development of its hereditary angioedema drug pipeline, as well as medical affairs.

"[Jennifer] brings a track record of successfully navigating the regulatory submission and approval process, as well as leading medical affairs activities and will be an invaluable member of our team as we continue to advance the lefamulin program toward a potential approval for the treatment of community-acquired bacterial pneumonia," Nabriva CEO Colin Broom said in a statement.